Wright Medical Group N.V. announced that the Centers for Medicare & Medicaid Services (CMS) published an update to the reimbursement calculation used to determine the transitional pass-through payment for the device category applicable to AUGMENT® Regenerative Solutions, including AUGMENT® Bone Graft and AUGMENT® Injectable, originally implemented on January 1, 2020. Based on this update, when hindfoot and ankle fusions are performed in the hospital outpatient and ambulatory surgical center settings of care, the facility will be paid for the incremental cost of AUGMENT, thereby facilitating Medicare beneficiary access to the advantages of AUGMENT by removing an economic barrier. This update is made retroactive to January 1, 2020, and the existing transitional device pass-through code (C1734) may be used to bill for AUGMENT for hindfoot and ankle fusion procedures when used in treatment of Medicare beneficiaries enrolled in Medicare Part B under the traditional Medicare program. Transitional pass-through payments are intended to facilitate Medicare beneficiary access to the advantages of new and innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure Ambulatory Payment Classifications rate. After rigorous vetting, the CMS concluded that AUGMENT is of great clinical utility in the outpatient setting and approved Wright’s application for transitional pass-through payment, which became effective January 1, 2020. This marked the first orthopedic implant to secure pass-through payment approval in over a decade, unlocking access to benefits for patients, physicians and facilities, including: AUGMENT improves patient outcomes by eliminating chronic pain associated with the autograft harvest site, which was found to be clinically significant at 52 weeks in 8.8% of patients and 5.2% of patients at an average follow-up of 9 years. AUGMENT was found to provide two times the odds ratio for fusion success on CT compared to autograft in patients 65 years of age or older. AUGMENT eliminates medically significant surgical complications associated with the autograft harvest from a second surgical site, which were found to occur in 8.9% (15/167) of patients in the AUGMENT clinical trials.